title: Bacille Calmette-Guérin/DNAhsp65 prime-boost is protective against diabetes in non-obese diabetic mice but not in the streptozotocin model of type 1 diabetes.
abstract: Type I diabetes is a disease caused by autoimmune destruction of the beta cells in the pancreas that leads to a deficiency in insulin production. The aim of this study was to evaluate the prophylactic potential of a prime-boost strategy involving bacille Calmette-Guérin (BCG) and the pVAXhsp65 vaccine (BCG/DNAhsp65) in diabetes induced by streptozotocin (STZ) in C57BL/6 mice and also in spontaneous type 1 diabetes in non-obese diabetic (NOD) mice. BCG/DNAhsp65 vaccination in NOD mice determined weight gain, protection against hyperglycaemia, decreased islet inflammation, higher levels of cytokine production by the spleen and a reduced number of regulatory T cells in the spleen compared with non-immunized NOD mice. In the STZ model, however, there was no significant difference in the clinical parameters. Although this vaccination strategy did not protect mice in the STZ model, it was very effective in NOD mice. This is the first report demonstrating that a prime-boost strategy could be explored as an immunomodulatory procedure in autoimmune diseases.
authors.affiliation: Department of Microbiology and Immunology, Biosciences Institute, Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brazil.
authors.forename: L C
authors.initials: LC
authors.lastname: da Rosa
authors.forename: F
authors.initials: F
authors.lastname: Chiuso-Minicucci
authors.forename: S F G
authors.initials: SF
authors.lastname: Zorzella-Pezavento
authors.forename: T G D
authors.initials: TG
authors.lastname: França
authors.forename: L L W
authors.initials: LL
authors.lastname: Ishikawa
authors.forename: P M
authors.initials: PM
authors.lastname: Colavite
authors.forename: B
authors.initials: B
authors.lastname: Balbino
authors.forename: L C B
authors.initials: LC
authors.lastname: Tavares
authors.forename: C L
authors.initials: CL
authors.lastname: Silva
authors.forename: C
authors.initials: C
authors.lastname: Marques
authors.forename: M R V
authors.initials: MR
authors.lastname: Ikoma
authors.forename: A
authors.initials: A
authors.lastname: Sartori
mesh_terms: D000818:Animals; D001500:BCG Vaccine / Q000235:genetics / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis; D003921:Diabetes Mellitus, Experimental / Q000276:immunology* / Q000517:prevention & control; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000517:prevention & control; D005260:Female; D007515:Islets of Langerhans / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D013311:Streptozocin / Q000009:adverse effects; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D001500:BCG Vaccine; D016207:Cytokines; D013311:Streptozocin
keywords: BCG; NOD mice; hsp65; immunomodulation; type 1 diabetes